MONTCLAIR, N.J., June 15, 2012 (GLOBE NEWSWIRE) -- FluoroPharma
Medical, Inc. (OTCBB:FPMI), a company specializing in the development
of novel diagnostic imaging products that utilize positron emission
tomography (PET) technology for the detection and assessment of disease
before clinical manifestation, is pleased to announce the appointment
of Thijs Spoor, to the position of Chairman of the Board. Mr. Spoor
will assume the role formerly held by Dr. David Elmaleh, who has left
the company. Mr. Spoor will also continue as President and CEO.

Mr. Spoor was appointed President and CEO of FluoroPharma Inc. on
September 15, 2010. He was previously CFO for Sunstone BioSciences.
Prior to joining Sunstone BioSciences, he worked as a consultant at
Oliver Wyman, focusing on pharmaceutical and medical device companies.
Mr. Spoor has also been an equity research analyst at J.P. Morgan and
Credit Suisse, covering the Biotechnology and Medical Device
industries. Mr. Spoor worked in the pharmaceutical industry, spending
10 years with Amersham / GE Healthcare where he oversaw the nuclear
cardiology portfolio and most recently as the Director of New Product
Opportunities leading the PET strategic plan.

Mr. Spoor holds a Nuclear Pharmacy degree from the University of
Toronto as well as an M.B.A. from Columbia University with
concentrations in finance and accounting.

About FluoroPharma Medical

FluoroPharma is a biopharmaceutical company engaged in the discovery
and development of proprietary PET imaging products to evaluate cardiac
disease at the cellular and molecular levels. The Company has licensed
technology from the Massachusetts General Hospital in Boston.

The Company's goal is to enable personalized medicine through advanced
imaging products that will help the medical community diagnose disease
more accurately at the earliest stages, leading to more effective
treatment, management and better patient outcomes.

The Company's initial focus is the development of breakthrough positron
emission tomography (PET) imaging agents for the efficient detection
and assessment of acute and chronic forms of coronary artery disease
(CAD). FluoroPharma is advancing two products in clinical trials for
assessment of acute and chronic forms of coronary disease. These first
in class agents have been designed to rapidly target myocardial cells.
Other products in development include agents for detection of inflamed
atherosclerotic plaque in peripheral arteries, agents with the
potential to image Alzheimer's disease and agents that could
potentially be used for imaging specific cancers.

In addition to the United States, Europe and China, patents related to
FluoroPharma's portfolio of imaging compounds have been issued in
Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico. For
more information on the Company, please visit: www.fluoropharma.com


CONTACT: Carol J. Perlman
         cperlman@fluoropharma.com
         917-592-9260